# Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

Source: https://onco.cc/trials/nct04421963/  
OnCo record `nct04421963` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is a phase 3 interventional study registered as NCT04421963 by AstraZeneca, with 185 participants enrolled, started 2020-08-04 and due to reach its primary completion in 2027-04-06. Interventions recorded: Olaparib. Conditions listed: Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04421963
- Phase: 3
- Setting: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
- Sponsor: AstraZeneca
- Enrolled: 185

## Sources

- ClinicalTrials.gov NCT04421963: https://clinicaltrials.gov/study/NCT04421963

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04421963.json